腔内治疗作为肾旁主动脉闭塞旁路手术替代方案:CHAOS(慢性腹主动脉闭塞,亚洲多中心)登记研究结果
本研究基于亚洲30个中心创建的CHAOS登记数据库,回顾性分析2007至2017年因肾下腹主动脉慢性完全闭塞行血运重建的患者,其中25家机构共130例肾旁主动脉闭塞患者(47例主-双髂/双股动脉旁路、32例腋-双股动脉旁路、51例腔内治疗)纳入分析。结果显示主-双髂/双股动脉旁路4年一期和二期通畅率显著高于腋-双股动脉旁路,作者认为对于可接受风险的患者主-双髂/双股动脉旁路仍是首选,而对于虚弱患者腔内治疗是优于腋-双股动脉旁路的良好选择。
要点
- 130例肾旁主动脉闭塞患者中,主-双髂/双股动脉旁路47例、腋-双股动脉旁路32例、腔内治疗51例。
- 住院期间死亡7例:主-双髂/双股动脉旁路组1例(2.1%)、腋-双股动脉旁路组1例(3.1%)、腔内治疗组5例(9.8%)。
- 4年一期和二期通畅率主-双髂/双股动脉旁路组(87.5%和90.3%)显著高于腋-双股动脉旁路组(66.7%和68.6%)。
核心结论
- 作者认为主-双髂/双股动脉旁路仍是金标准,对于可接受风险的患者应作为首选。
- 作者认为对于虚弱患者,腔内治疗是良好选择,且与腋-双股动脉旁路相比可能更宜作为一线治疗。
研究设计与样本
- 回顾性分析亚洲30个中心创建的CHAOS(慢性腹主动脉闭塞,亚洲多中心)登记数据库。
- 纳入2007至2017年因肾下腹主动脉慢性完全闭塞行血运重建的患者。
- 436例患者中,来自25家机构的130例肾旁主动脉闭塞患者纳入本研究:主-双髂/双股动脉旁路47例、腋-双股动脉旁路32例、腔内治疗51例。
主要发现
- 腋-双股动脉旁路组和腔内治疗组患者年龄显著大于主-双髂/双股动脉旁路组,腔内治疗组营养不良者多于主-双髂/双股动脉旁路组。
- 腔内治疗尝试失败1例。
- 住院期间死亡7例:主-双髂/双股动脉旁路组1例(2.1%)、腋-双股动脉旁路组1例(3.1%)、腔内治疗组5例(9.8%),腔内治疗组多数死亡原因与血运重建手术无关。
- 未观察到所担心的内脏栓塞,尽管腔内治疗组仅2例进行了保护。
- 最新随访(中位时长3.0年)时,踝肱压力指数由高到低依次为主-双髂/双股动脉旁路、腔内治疗、腋-双股动脉旁路。
临床怎么用
- 作者认为主-双髂/双股动脉旁路仍是金标准,对于可接受风险的患者应作为首选。
- 作者认为对于虚弱患者,腔内治疗是良好选择,且与腋-双股动脉旁路相比可能更宜作为一线治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Juxtarenal aortic occlusion (JRAO), in which the occlusion of the aorta extends to just below the renal artery, is often treated by bypass surgery because of concerns about the risk of procedural failure and fatal embolization to abdominal organs when treated with endovascular treatment (EVT). This study assessed the outcome of EVT for JRAO compared with aorto-biiliac /aorto-bifemoral (AOB) or axillo-bifemoral (AXB) bypass. METHODS: A retrospective review of an international database created by 30 centers in Asia (CHronic Abdominal Aortic Occlusion, ASian Multicenter registry) was performed for patients who underwent revascularization for chronic total occlusion of the infrarenal aorta from 2007 to 2017. Of the 436 patients, 130 with JRAO (Forty-seven AOBs, 32 AXBs, and 51 EVTs) from 25 institutions were included in this study. RESULTS: Patients were significantly older in the AXB and EVT groups and more malnourished in the EVT group than the AOB group. EVT was attempted but failed in 1 patient. Seven patients (1 [2.1%] in the AOB group, 1 [3.1%] in the AXB group, and 5 [9.8%] in the EVT group) died during hospitalization, but most of the causes in the EVT group were not related to the revascularization procedure. No visceral embolism was observed, which had been concerned, even though protection was performed only in 2 cases of the EVT group. At the latest follow-up (median duration 3.0 years), the ankle-brachial pressure index was significantly higher in the order of AOB, EVT, and AXB. At 4 years, the estimated primary and secondary patency rates of the AOB group (87.5% and 90.3%, respectively) were significantly higher than the AXB group (66.7% and 68.6%, respectively). CONCLUSIONS: AOB remains the gold standard and should be the first choice for acceptable risk patients. For frail patients, EVT is a good option and likely preferable as a first-line treatment compared to AXB.
引用
- Kawai Y, Fujimura N, Obara H, et al. Endovascular Treatment as an Alternative to Bypass Surgery for Juxtarenal Aortic Occlusion: Results from the CHAOS (CHronic Abdominal Aortic Occlusion, ASian Multicenter) Registry. Ann Vasc Surg. 2024. PMID: 38492723. doi:10.1016/j.avsg.2023.12.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。